Agenus Inc. has broadened its global Medical Affairs team to meet a surge in physician requests for its investigational botensilimab plus balstilimab (BOT+BAL) combination. The expansion is designed to streamline safety monitoring, regulatory coordination, and real‑world data collection for patients receiving BOT+BAL through France’s Authorisation d’Accès Compassionnel (AAC) program and paid named‑patient programs in other markets.
The French AAC framework was recently updated on January 12, 2026 to include microsatellite‑stable metastatic colorectal cancer, platinum‑resistant ovarian cancer, and advanced soft‑tissue sarcomas. Agenus has also been supplying BOT+BAL under paid named‑patient programs in South and Central America, the United Kingdom, and Switzerland, providing early access while gathering evidence that could support future regulatory submissions.
Agenus’ financial profile underscores the urgency of this expansion. The company has posted consecutive net losses and relies on external funding to sustain operations. A $141 million collaboration with Zydus Lifesciences earlier this year secured manufacturing capacity and a cash infusion, but liquidity remains tight. The new Medical Affairs resources are intended to generate early revenue streams and strengthen the company’s balance sheet by monetizing access programs.
Regulatory hurdles remain significant. The U.S. Food and Drug Administration previously advised against accelerated approval of BOT+BAL for microsatellite‑stable metastatic colorectal cancer, citing insufficient survival benefit data. Ongoing Phase 3 BATTMAN trials and other studies are critical to building the evidence base needed for eventual approval. The expanded infrastructure will support the collection of robust safety and efficacy data that could mitigate regulatory risk.
Chairman and CEO Garo Armen emphasized that the expansion reflects growing physician interest driven by maturing clinical evidence. “As clinical data for BOT+BAL continue to mature, we are seeing increasing inquiries from physicians seeking access for patients with limited options,” he said. “Expanding our Medical Affairs team ensures we can respond with scientific rigor, safeguard patient safety, and position the program for disciplined execution across authorized access pathways and late‑stage development.”
The move signals Agenus’ commitment to translating clinical momentum into tangible access and revenue opportunities while navigating a challenging financial and regulatory landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.